Андрианов А.М.1, Фурс К.В.2, Гончар А.В.2, Асланян Л.А.3, Тузиков А.В.2
Применение технологий виртуального скрининга и молекулярного моделирования для идентификации потенциальных ингибиторов основной протеазы коронавируса SARS-CoV-2
Математическая биология и биоинформатика. 2023;18(1):15-32.
doi: 10.17537/2023.18.15.
Список литературы
- Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., Wang W., Song H., Huang B., Zhu N. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–574. doi: 10.1016/S0140-6736(20)30251-8
- Chan J.F.-W., Yuan S., Kok K.-H., To K. K.-W., Chu H., Yang J., Xing F., Liu J., Yip C. C.-Y., Poon R. W.-S., et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395:514–523. doi: 10.1016/S0140-6736(20)30154-9
- Yan F., Gao F. An overview of potential inhibitors targeting non-structural proteins 3 (PLpro and Mac1) and 5 (3CLpro/Mpro) of SARS-CoV-2. Comput. Struct. Biotechnol. J. 2021;19:4868–4883. doi: 10.1016/j.csbj.2021.08.036
- Ullrich S., Nitsche C. The SARS-CoV-2 main protease as drug target. Bioorg. Med. Chem. Lett. 2020;30. Article No. 127377. doi: 10.1016/j.bmcl.2020.127377
- Katre S.G., Asnani A.J., Pratyush K., Sakharkar N.G., Bhope A.G., Sawarkar K.T., Nimbekar V.S. Review on development of potential inhibitors of SARS-CoV-2 main protease (MPro). Futur. J. Pharm. Sci. 2022;8. Article No. 36. doi: 10.1186/s43094-022-00423-7
- Xia S., Chan J. F.-W., Wang L, Jiao F., Chik K. K.-H., Chu H., Lan Q., Xu W., Wang Q., Wang C., Yuen K-Y., Lu L., Jiang S. Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant. Cell Res. 2022;32:404–406. doi: 10.1038/s41422-022-00617-x
- Xia S., Liu M., Wang C., Xu W., Lan Q., Feng S., Qi F., Bao L., Du L., Liu S., Qin C., Sun F., Shi Z., Zhu Y., Jiang S., Lu L. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020;30:343–355. doi: 10.1038/s41422-020-0305-x
- Tao K., Tzou P.L., Nouhin J., Bonilla H., Jagannathan P., Shafer R.W. SARS-CoV-2 antiviral therapy. Clin. Microbiol. Rev. 2022;34(4). Article No. e0010921. doi: 10.1128/CMR.00109-21
- Niknam Z., Jafari A., Golchin A., Pouya F.D., Nemati M., Rezaei-Tavirani M., Rasmi Y. Potential therapeutic options for COVID-19: an update on current evidence. Eur. J. Med. Res. 2022;27. Article No. 6. doi: 10.1186/s40001-021-00626-3
- Zhang Y., Ye T., Xi H., Juhas M., Li J. Deep learning driven drug discovery: Tackling Severe Acute Respiratory Syndrome Coronavirus 2. Front. Microbiol. 2021. doi: 10.3389/fmicb.2021.739684
- Pillaiyar T., Manickam M., Namasivayam V.M., Hayashi Y., Jung S. H. An overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL protease inhibitors: Peptidomimetics and small molecule chemotherapy. J. Med. Chem. 2016;59:6595–6628. doi: 10.1021/acs.jmedchem.5b01461
- Chen Y., Liu Q., Guo D. Coronaviruses: genome structure, replication, and pathogenesis. J. Med. Virol. 2020;92(4):418–423. doi: 10.1002/jmv.25681
- Colson P., Rolain J.M., Lagier J.C., Brouqui P., Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int. J. Antimicrob Agents. 2020;55(4). Article No. 105932. doi: 10.1016/j.ijantimicag.2020.105932
- Dong L.Y., Hu S.S., Gao J.J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). DD & T. 2020;1:58–60. doi: 10.5582/ddt.2020.01012
- Balakrishnan V., Lakshminarayanan K. Screening of FDA Approved Drugs Against SARS-CoV-2 Main Protease: Coronavirus Disease. Int. J. Pept. Res. Ther. 2021;27(1):651–658. doi: 10.1007/s10989-020-10115-6
- Pendyala B., Patras A. In silico screening of food bioactive compounds to predict potential inhibitors of COVID-19 main protease (Mpro) and RNA-dependent RNA polymerase (RdRp). ChemRxiv. 2022. doi: 10.26434/chemrxiv.12051927.v2
- Owen D.R., Allerton C.M., Anderson A.S., Aschenbrenner L., Avery M., Berritt S., Boras B., Cardin R.D., Carlo A., Coffman K.J. et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374(6575):1586–1593. doi: 10.1126/science.abl4784
- U.S. Food and Drug Administration. https://www.fda.gov/ (accessed 10.02.2023).
- Shuldau N.A., Yushkevich A.M., Furs K.V., Tuzikov A.V., Andrianov A.M. Development of a Deep Learning Generative Neural Network for Computer-Aided Design of Potential SARS-Cov-2 Inhibitors. Mathematical Biology and Bioinformatics. 2022;17(2):188–207. doi: 10.17537/2022.17.188
- Dalby A., Nourse J.G., Hounshell W.D., Gushurst A.K.I., Grier D.L., Leland B.A, Laufer J. Description of several chemical structure file formats used by computer programs developed at Molecular Design Limited. J. Chem. Inf. Comp. Sc. 1992;32(3):244–255. doi: 10.1021/ci00007a012
- Wishart D.S., Feunang Y.D., Guo A.C., Lo E.J., Marcu A., Grant J.R., Sajed T., Johnson D., Li C., Sayeeda Z. et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucl. Acids Res. 2017;46:D1074–D1082. doi: 10.1093/nar/gkx1037
- Sterling T., Irwin J.J. ZINC 15 – Ligand discovery for everyone. J. Chem. Inf. Model. 2015;55(11):2324–2337. doi: 10.1021/acs.jcim.5b00559
- Trott O., Olson A.J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comp. Chem. 2010;31:455–461. doi: 10.1002/jcc.21334
- Wójcikowski M., Ballester P., Siedlecki P. Performance of machine-learning scoring functions in structure-based virtual screening. Sci. Rep. 2017;7. Article No. 46710. doi: 10.1038/srep46710
- Durrant J.D., McCammon J.A. NNScore 2.0: A neural-network receptor–ligand scoring function. J. Chem. Inf. Model. 2011;51(11):2897–2903. doi: 10.1021/ci2003889
- Palacio-Rodríguez K., Lans I., Cavasotto C.N., Cossio P. Exponential consensus ranking improves the outcome in docking and receptor ensemble docking. Sci. Rep. 2019;9(1). Article No. 5142. doi: 10.1038/s41598-019-41594-3
- Case D.A., Ben-Shalom I.Y., Brozell S.R., Cerutti D.S., Cheatham T.E., III, Cruzeiro V.W.D., Darden T.A., Duke R.E., Ghoreishi D., Gilson M.K. et al. AMBER 2018. University of California, 2018.
- Jorgensen W.L., Chandrasekhar J., Madura J.D., Impey R.W., Klein, M.L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 1983;79(2):926–935. doi: 10.1063/1.445869
- Ryckaert J.P., Ciccotti G., Berendsen H.J.C. Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J. Comput. Phys. 1977;23(3):327–341. doi: 10.1016/0021-9991(77)90098-5
- Essmann U., Perera L., Berkowitz M.L., Darden T., Lee H., Pedersen L.G. A smooth particle mesh Ewald method. J. Chem. Phys. 1995;103:8577–8593. doi: 10.1063/1.470117
- Durrant J.D., McCammon, J.A. BINANA: A novel algorithm for ligand-binding characterization. J. Mol. Graph. Model. 2011;29(6):888–893. doi: 10.1016/j.jmgm.2011.01.004
- Genheden S., Ryde U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinity. Expert Opin. Drug Discov. 2015;10(5):449–461. doi: 10.1517/17460441.2015.1032936
- Zhang C.H., Stone E.A., Deshmukh M., Ippolito J.A., Ghahremanpour M.M., Tirado-Rives J., Spasov K.A., Zhang S., Takeo Y., Kudalkar S.N. et al. Potent noncovalent inhibitors of the Main Protease of SARS-CoV-2 from molecular sculpting of the drug perampanel guided by free energy perturbation calculations. ACS Cent Sci. 2021;7(3):467–475. doi: 10.1021/acscentsci.1c00039
- Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001;46:3–26.
- Qamar M.T., Alqahtani S.M., Alamri M.A., Chen L.-L. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. J. Pharm. Anal. 2020;10(4):313–319. doi: 10.1016/j.jpha.2020.03.009
- Daina A., Michielin O., Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017;7. Article No. 42717. doi: 10.1038/srep42717
- Shen C., Hu Y., Wang Z., Zhong H., Zhang H., Zhong H., Wang G., Yao X., Xu L., Cao D., Hou T. Can machine learning consistently improve the scoring power of classical scoring functions? Insights into the role of machine learning in scoring functions. Brief. Bioinf. 2021;22(1):497–514. doi: 10.1093/bib/bbz173
|
|
|